Prostate cancer: alkaline phosphatase predicts OS, risk for bone mets

L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. Inscrivez-vous gratuitement
Takeaway
  • Rapid alkaline phosphatase velocity (APV) predicted shorter OS and bone metastasis-free survival (BMFS) in patients with castration-resistant prostate cancer (CRPC).

Why this matters

  • 12% of patients with organ-confined prostate cancer at initial presentation develop bone metastases (BM). 
  • <1% of these patients survive ≥5 y. 
  • Efficacy of PSA doubling time (PSADT) in predicting BM in patients with rising PSA is limited. 
  • Present findings confirm previous evidence of the benefit of APV+PSADT for risk stratification. 
  • Racial/ethnic composition of this study is more representative of the general US population than previous cohorts, making it more generalizable.
Study design
  • Retrospective cohort study evaluated 89 patients with CRPC who received androgen depriv...